Roche Increases Offer for Genentech
SETTING THE RECORD STRAIGHT
An article about Roche's offer to buy Genentech incorrectly attributed this quote: "Roche is going to get this deal done. That's what this move tells everyone. It should convince people that Roche is not going to walk away from this." The comment was made by Oppenheimer & Co. analyst Bret Holley.
Roche also extended its offer to shareholders by a week, until March 20. Genentech has already urged its shareholders to reject the $86.50-a-share bid, saying Genentech is worth $112 a share. Franz B. Humer, the chairman of Roche, said in an interview on Friday that the new offer was made to speed the process after conversations the company had with Genentech shareholders.
Read More
Arizona Internet Marketing
Arizona Biotechnology Marketing
Biotechnology News
An article about Roche's offer to buy Genentech incorrectly attributed this quote: "Roche is going to get this deal done. That's what this move tells everyone. It should convince people that Roche is not going to walk away from this." The comment was made by Oppenheimer & Co. analyst Bret Holley.
Roche also extended its offer to shareholders by a week, until March 20. Genentech has already urged its shareholders to reject the $86.50-a-share bid, saying Genentech is worth $112 a share. Franz B. Humer, the chairman of Roche, said in an interview on Friday that the new offer was made to speed the process after conversations the company had with Genentech shareholders.
Read More
Arizona Internet Marketing
Arizona Biotechnology Marketing
Biotechnology News
Labels: Arizona, Arizona Biotech, Genentech, Roche
posted by Bill Austin - Roche Increases Offer for Genentech
0 Comments:
Post a Comment
Links to this post:
Create a Link
<< Home